Poland
# |
Name |
Current Liabilities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 955.01 M
|
Dec. 31, 2023 | USD 208.13 | 0.81% |
|
Poland |
|
2 |
USD 41.99 M
|
Dec. 31, 2023 | USD 0.90 | -1.27% |
|
Poland |
|
3 |
USD 35.29 M
|
Sept. 30, 2024 | USD 58.16 | 0.74% |
|
Poland |
|
4 |
USD 34.43 M
|
Dec. 31, 2023 | USD 5.15 | -3.61% |
|
Poland |
|
5 |
USD 31.04 M
|
Dec. 31, 2023 | USD 2.85 | 0.09% |
|
Poland |
|
6 |
USD 28.48 M
|
Dec. 31, 2023 | USD 36.63 | -0.24% |
|
Poland |
|
7 |
USD 23.78 M
|
Dec. 31, 2023 | USD 10.78 | -0.36% |
|
Poland |
|
8 |
USD 21.89 M
|
Dec. 31, 2023 | USD 5.95 | -0.32% |
|
Poland |
|
9 |
USD 17.68 M
|
Dec. 31, 2023 | USD 6.78 | -1.52% |
|
Poland |
|
10 |
USD 14.03 M
|
Dec. 31, 2023 | USD 2.29 | -0.01% |
|
Poland |
|
11 |
USD 7.86 M
|
Dec. 31, 2023 | USD 1.23 | 1.32% |
|
Poland |
|
12 |
USD 6.78 M
|
Dec. 31, 2023 | USD 12.77 | 1.67% |
|
Poland |
|
13 |
USD 4.69 M
|
Dec. 31, 2023 | USD 9.53 | -0.94% |
|
Poland |
|
14 |
USD 2.65 M
|
Dec. 31, 2023 | USD 3.74 | 1.10% |
|
Poland |
|
15 |
USD 1.56 M
|
Dec. 31, 2023 | USD 40.34 | 2.10% |
|
Poland |
|
16 |
USD 797.29 K
|
Dec. 31, 2023 | USD 1.78 | -1.14% |
|
Poland |
|
17 |
USD 542.53 K
|
Dec. 31, 2023 | USD 21.83 | 2.30% |
|
Poland |
|
18 |
USD 449.11 K
|
Dec. 31, 2023 | USD 1.15 | -0.76% |
|
Poland |
|
19 |
USD 293.15 K
|
Dec. 31, 2023 | USD 1.88 | 0.22% |
|
Poland |
The Biotechnology company in Poland with the highest Current Liabilities is NEUCA S.A. (Warsaw Stock Exchange: NEU.WA) at USD 955.01 M.
The Biotechnology company in Poland with the lowest Current Liabilities is Medinice S.A. (Warsaw Stock Exchange: ICE.WA) at USD 293.15 K.
The top 10 Biotechnology companies in Poland by Current Liabilities are NEUCA S.A., BIOTON S.A., Synektik Spólka Akcyjna, Centrum Medyczne ENEL-MED S.A., EMC Instytut Medyczny SA, Voxel S.A., Selvita S.A., Celon Pharma S.A., Ryvu Therapeutics S.A. and Mabion S.A..
The bottom 10 Biotechnology companies in Poland by Current Liabilities are Medinice S.A., Pharmena S.A., Bioceltix S.A., Genomtec S.A., Scope Fluidics S.A., BioMaxima S.A., Poltreg S.A., Captor Therapeutics Spolka Akcyjna, Synthaverse S.A. and Mabion S.A..